GOSSAMER BIO, INC. (GOSS) Quick Ratio
- Quick ratio · latest quarter: Value 0.46×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 0.46× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $63.13M ÷ $137.78M ≈ 0.46× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 63.13M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 137.78M USD | Liabilities, Current |
| Cash and equivalents | 41.15M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 15.88M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 6.11M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $63.13M | $137.78M | $41.15M | $15.88M | $6.11M | (m) | 0.46× |
| 2026-03-31 | $108.47M | $56.51M | $41.03M | $58.19M | $9.25M | (m) | 1.92× |
| 2025-12-31 | $149.16M | $63.44M | $37.73M | $99.20M | $12.23M | (m) | 2.35× |
| 2025-09-30 | $189.47M | $62.12M | $8.93M | $171.29M | $9.24M | (m) | 3.05× |
| 2025-06-30 | $220.50M | $53.59M | $26.31M | $186.61M | $7.58M | (m) | 4.11× |
| 2025-03-31 | $264.52M | $48.22M | $29.02M | $228.91M | $6.58M | (m) | 5.49× |
| 2024-12-31 | $299.86M | $45.01M | $46.07M | $248.44M | $5.34M | (m) | 6.66× |
| 2024-09-30 | $333.62M | $51.09M | $28.46M | $298.57M | $6.59M | (m) | 6.53× |
| 2024-06-30 | $358.12M | $45.19M | $86.88M | $267.61M | $3.63M | (m) | 7.93× |
| 2024-03-31 | (m) | $35.82M | $38.86M | $205.53M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $51.60M | $32.11M | $264.32M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $42.32M | $82.61M | $246.28M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $40.14M | $37.00M | $125.12M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $40.57M | $65.24M | $136.61M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $49.23M | $111.97M | $143.71M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $52.65M | $153.48M | $150.91M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $44.41M | $94.32M | $127.84M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $34.57M | $138.91M | $132.72M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $39.86M | $183.40M | $141.81M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $35.90M | $213.47M | $152.55M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $29.98M | $342.45M | $63.47M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $29.44M | $439.66M | $13.64M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $38.65M | $486.06M | $26.57M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $32.61M | $461.96M | $93.42M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $27.54M | $486.06M | $114.30M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $28.36M | $111.35M | $234.81M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $36.92M | $135.09M | $266.74M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $33.17M | $130.71M | $315.76M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $27.51M | $148.50M | $315.50M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $25.15M | $170.85M | $310.37M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $20.40M | $105.22M | $123.44M | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |